MetaVia Announces Completion of Last Patient Visit in Extended 24-Week Phase 1 Part 3A Study of DA-1726

MetaVia Inc. (MTVA) filed an SEC Form 8-K — Regulation FD Disclosure. Exhibit 99.1 ​ ​ ​ ​ ​ MetaVia Announces Completion of Last Patient Visit in Extended 24-Week Phase 1 Part 3A Study of DA-1726 ​ Encouraging Preliminary Safety and Tolerability Observations in Part 3A Supported Decision to Extend Treatment from 16 to 24 Weeks ​ Positive Part 3B I

Event · Clinical / regulatory
Product
DA-1726

Facts are quoted from the filing text and checked against it.

Original reporting
Published Nov 17, 2026, 2:01 PM UTC
Analysis
AlphAI AI DeskAI-generated
Added to AlphAI Nov 17, 2026, 2:02 PM UTC. Informational, not investment advice.
How this was made
AlphAI summarizes source reporting and applies a structured AI analysis for relevance, timing, sentiment and ticker impact. Always verify material claims with the original publisher.
AlphAI market briefFinancial news
Primary signal
$MTVA
Bullish
medium confidence
Mentioned
$MTVA
Relevance
7/10
AlphAI data visualization · based on SEC EDGAR 8-K
Decision brief

The 30-second read

$MTVABullishMed
01

Why it matters

The company’s decision to extend treatment duration from 16 to 24 weeks after preliminary safety/tolerability observations, plus the completion of the last Part 3A patient visit, reduces near-term execution risk and supports continued development planning toward a 48-week Phase 2 study targeted for second-half 2027.

02

Market read

Traders may view this as a positive pipeline execution milestone that supports the probability of progressing to Phase 2, while awaiting the full Parts 3A and 3B dataset in Q1 2027.

03

What to watch

The article does not provide new safety signals beyond the extension rationale, and it does not quantify adverse events or durability beyond the stated extension framework.

Relevance 7/10Novelty 6/10Timing: today’s SEC EDGAR 8-K, ahead of full Parts 3A and 3B data expected in Q1 2027

Background

MetaVia is running a Phase 1 trial for DA-1726, a once-weekly GLP-1R/GCGR dual agonist, with Parts 3A and 3B designed to support Phase 2 readiness in metabolic and alcohol-associated liver disease.

Company-level read

Ticker impact

$MTVABullishMedium confidence
Context

MetaVia reports last patient completed the Phase 1 Part 3A visit for DA-1726 and extends treatment from 16 to 24 weeks.

Expected impact

Likely upward bias as the market prices improved clinical execution and durability/safety read-through ahead of full Part 3A and 3B data.

Evidence & confidence

The filing is a primary clinical update (last visit completed) plus a stated extension decision driven by preliminary safety/tolerability, alongside previously released Part 3B interim efficacy.

Market effects

Adds incremental momentum to the liver disease GLP-1/GCGR dual-agonist competitive set, potentially influencing sentiment toward early-stage metabolic/liver biotech programs.

Primarily US-listed biotech sentiment via Nasdaq-listed clinical-stage risk appetite.

Limited direct global macro impact; relevant mainly to global investors tracking metabolic and alcohol-associated liver disease pipelines.

Counterpoint

The update is executional (last visit completed) and the key Phase 2 decision hinges on full Part 3A and 3B data, which is still months away.

Key entities

  • MetaVia Inc.

    Nasdaq-listed clinical-stage biotech developing DA-1726 for liver-related cardiometabolic diseases.

  • DA-1726

    Once-weekly GLP-1R/GCGR dual-receptor agonist being evaluated in Phase 1 Parts 3A and 3B.

  • Precision Liver Symposium 2026

    Conference where Part 3B interim data were presented.

Related articles

$MTVAMed

MetaVia completes phase 1 trial of liver disease drug DA-1726

MetaVia Inc. (MTVA) completed its Phase 1 trial for DA-1726, a drug for liver-related cardiometabolic diseases. The trial extended treatment to 24 weeks, showing a 68.1% placebo-adjusted reduction in liver fat and 13.5% weight loss. Full data is expected in Q1 2027, with a Phase 2 study planned for late 2027. DA-1726 is a once-weekly subcutaneous treatment.

$MTVAMed

MetaVia Announces Completion of Last Patient Visit in Extended 24-Week Phase 1 Part 3A Study of DA-1726

MetaVia Inc. (MTVA) completed its Phase 1 clinical trial for DA-1726, a novel GLP-1/glucagon dual-receptor agonist. The treatment period was extended to 24 weeks, with encouraging safety and tolerability data. Part 3B interim results showed a 68.1% placebo-adjusted reduction in liver fat and 13.5% weight loss. Full data is expected in Q1 2027, with a Phase 2 study planned for H2 2027.

$MTVAMedAI 8/10

MetaVia Presents Preclinical Data Supporting the Potential of DA-1726 to Address Liver Disease and Weight Loss at ObesityWeek® 2026

MetaVia Inc. (MTVA) filed an SEC Form 8-K — Other Events. Exhibit 99.1 ​ ​ ​ ​ ​ MetaVia Presents Preclinical Data Supporting the Potential of DA-1726 to Address Liver Disease and Weight Loss at ObesityWeek® 2026 ​ Statistically Significant Increase in Liver and Circulating FGF21 Expression ​ Greater Glucose Lowering and Comparable Weig

$MTVAMedAI 8/10

MetaVia Presents Preclinical Data Supporting the Potential of DA-1726 to Address Liver Disease and Weight Loss at ObesityWeek® 2026

MetaVia Inc. (MTVA) presented preclinical data at ObesityWeek 2026, showing its drug DA-1726 increased liver FGF21 expression and achieved weight loss comparable to retatrutide with less food intake suppression. The company plans to start a Phase 2 study for MetALD and ALD in late 2027. DA-1726 demonstrated greater glucose lowering and favorable lipid effects. According to MetaVia, the results support DA-1726's potential in liver-related cardiometabolic diseases.